Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia (VERONE)

AbbVie

Status: Active, not recruiting

Conditions: Cancer - Chronic Lymphocytic Leukemia

Study type: Observational

Funder types: Industry

Identifiers

NCT03415035

P16-913

Details and patient eligibility

About

This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).

Enrollment: 269 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
• Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
• Participants the physician believes he can personally follow over all the study period.
• Participants who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control.

Exclusion criteria

• Participating in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation.

Trial design

269 participants in 1 patient group

Patients with Chronic Lymphocytic Leukemia (CLL)

Description:

Patients with diagnosed CLL and eligible to venetoclax as per label